




# PHARMACEUTICAL 2023

Transcode Therapeutics Inc.  
Rank 390 of 446





# PHARMACEUTICAL 2023

Transcode Therapeutics Inc.  
Rank 390 of 446

The relative strengths and weaknesses of Transcode Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Transcode Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 17% points. The greatest weakness of Transcode Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 175% points.

The company's Economic Capital Ratio, given in the ranking table, is -201%, being 244% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7,379
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,347
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,101
Other Revenues	0
Property and Equipment	209
Research and Development	10,232
Selling, General and Administrative Expense	8,433

Output Variable	Value in 1000 USD
Assets	7,588
Liabilities	4,347
Expenses	18,666
Revenues	0
Stockholders Equity	3,241
Net Income	-17,565
Comprehensive Net Income	-17,565
Economic Capital Ratio	-201%